Pasar al contenido principal

PAPEL DE SUMO EN EL DESARROLLO Y LA ENFERMEDAD

PGC2018-094232-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento Científico y Tecnológico del Sistema de I+D+i
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Relevance of BET Family Proteins in SARS-CoV-2 Infection

  • Lara-Ureña, Nieves
  • García-Domínguez, Mario
The recent pandemic we are experiencing caused by the coronavirus disease 2019 (COVID-19) has put the world’s population on the rack, with more than 191 million cases and more than 4.1 million deaths confirmed to date. This disease is caused by a new type of coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A massive proteomic analysis has revealed that one of the structural proteins of the virus, the E protein, interacts with BRD2 and BRD4 proteins of the Bromodomain and Extra Terminal domain (BET) family of proteins. BETs are essential to cell cycle progression, inflammation and immune response and have also been strongly associated with infection by different types of viruses. The fundamental role BET proteins play in transcription makes them appropriate targets for the propagation strategies of some viruses. Recognition of histone acetylation by BET bromodomains is essential for transcription control. The development of drugs mimicking acetyl groups, and thereby able to displace BET proteins from chromatin, has boosted interest on BETs as attractive targets for therapeutic intervention. The success of these drugs against a variety of diseases in cellular and animal models has been recently enlarged with promising results from SARS-CoV-2 infection studies., Research at M.G.-D. lab is currently supported by grants PGC2018-094232-B-I00 from Ministry of Science, Innovation and Universities (MICIU), Spain, and CV20-93141 from regional government from Andalusia (both co-financed by the European Regional Development Fund)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

BETting on a Transcriptional Deficit as the Main Cause for Cornelia de Lange Syndrome

  • García-Gutiérrez, Pablo
  • García-Domínguez, Mario
Cornelia de Lange Syndrome (CdLS) is a human developmental syndrome with complex multisystem phenotypic features. It has been traditionally considered a cohesinopathy together with other phenotypically related diseases because of their association with mutations in subunits of the cohesin complex. Despite some overlap, the clinical manifestations of cohesinopathies vary considerably and, although their precise molecular mechanisms are not well defined yet, the potential pathomechanisms underlying these diverse developmental defects have been theoretically linked to alterations of the cohesin complex function. The cohesin complex plays a critical role in sister chromatid cohesion, but this function is not affected in CdLS. In the last decades, a non-cohesion-related function of this complex on transcriptional regulation has been well established and CdLS pathoetiology has been recently associated to gene expression deregulation. Up to 70% of CdLS cases are linked to mutations in the cohesin-loading factor NIPBL, which has been shown to play a prominent function on chromatin architecture and transcriptional regulation. Therefore, it has been suggested that CdLS can be considered a transcriptomopathy. Actually, CdLS-like phenotypes have been associated to mutations in chromatin-associated proteins, as KMT2A, AFF4, EP300, TAF6, SETD5, SMARCB1, MAU2, ZMYND11, MED13L, PHIP, ARID1B, NAA10, BRD4 or ANKRD11, most of which have no known direct association with cohesin. In the case of BRD4, a critical highly investigated transcriptional coregulator, an interaction with NIPBL has been recently revealed, providing evidence on their cooperation in transcriptional regulation of developmentally important genes. This new finding reinforces the notion of an altered gene expression program during development as the major etiological basis for CdLS. In this review, we intend to integrate the recent available evidence on the molecular mechanisms underlying the clinical manifestations of CdLS, highlighting data that favors a transcription-centered framework, which support the idea that CdLS could be conceptualized as a transcriptomopathy., Research at our lab is currently supported by grants PGC 2018-094232-B-I00 from Ministry of Science, Innovation and Universities (MICIU), Spain, and CV20-93141 from regional government from Andalusia (both co-financed by the European regional development fund), to MG-D., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases

  • Lara-Ureña, Nieves
  • Jafari, Vahid
  • García-Domínguez, Mario
SUMOylation is a post-translational modification that has emerged in recent decades as a mechanism involved in controlling diverse physiological processes and that is essential in vertebrates. The SUMO pathway is regulated by several enzymes, proteases and ligases being the main actors involved in the control of sumoylation of specific targets. Dysregulation of the expression, localization and function of these enzymes produces physiological changes that can lead to the appearance of different types of cancer, depending on the enzymes and target proteins involved. Among the most studied proteases and ligases, those of the SENP and PIAS families stand out, respectively. While the proteases involved in this pathway have specific SUMO activity, the ligases may have additional functions unrelated to sumoylation, which makes it more difficult to study their SUMO-associated role in cancer process. In this review we update the knowledge and advances in relation to the impact of dysregulation of SUMO proteases and ligases in cancer initiation and progression., This research was funded by MICIN/AEI/10.13039/501100011033, Spain/ERDF “A way to make Europe”, European Union, grant number PGC2018-094232-B-I00.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proper progression of neurogenesis relies on a defined pattern of SUMO-modified proteins

  • García-Domínguez, Mario
Neurogenesis is a complex process involving the orchestration of many transcription factors and other proteins. Fine regulation of their activities is crucial for proper progression of neurogenesis. A few decades ago, covalent attachment of Small Ubiquitin-like MOdifier (SUMO) to other proteins was revealed as a major regulator of protein activities, constituting an essential posttranslational modification system in vertebrates. Since then, hundreds of proteins have been shown to be targets of SUMO, which is implicated in controlling many relevant processes in eukaryotic cells. These include the development and function of the nervous system, with SUMO tightly linked to synapsis and to neurodegenerative diseases (Yau et al., 2020). The SUMO protease SENP7 has been involved in neurogenesis (Juárez-Vicente et al., 2016), while sumoylation of BRAF35, a subunit of the LSD1 histone demethylase complex, assures the undifferentiated state of neural progenitors (Ceballos-Chávez et al., 2012). In addition, increased sumoylation in mouse brain-derived neural stem cells results in enhanced neuronal differentiation (Bernstock et al., 2019). However, in general, the implication of SUMO in neuronal differentiation and nervous system development has been poorly studied. We have recently developed a proteomic study aimed at identifying SUMO targets associated either with proliferation or with neuronal differentiation conditions, which has highlighted the relevance of SUMO modification for proper progression of neurogenesis. Here, we discuss our recent results, present specific SUMO targets that are key to the process, and indicate future research directions to uncover the molecular mechanisms underlying SUMO modification of relevant neurogenesis-associated factors., Research at the MGD lab is currently supported by grants PGC2018-094232-B-I00 from the Ministry of Science, Innovation and Universities (MICIU), Spain, and CV20-93141 from the Andalusian regional government (both co-financed by the European Regional Development Fund). We apologize to those authors not cited here due to space limitations.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SUMO control of nervous system development

  • García-Gutiérrez, Pablo
  • García-Domínguez, Mario
In the last decades, the post-translational modification system by covalent attachment of the SUMO polypeptide to proteins has emerged as an essential mechanism controlling virtually all the physiological processes in the eukaryotic cell. This includes vertebrate development. In the nervous system, SUMO plays crucial roles in synapse establishment and it has also been linked to a variety of neurodegenerative diseases. However, to date, the involvement of the modification of specific targets in key aspects of nervous system development, like patterning and differentiation, has remained largely elusive. A number of recent works confirm the participation of target-specific SUMO modification in critical aspects of nervous system development. Here, we review pioneering and new findings demonstrating the essential role SUMO plays in neurogenesis and other facets of neurodevelopment, which will help to precisely understand the variety of mechanisms SUMO utilizes to control most fundamental processes in the cell., Research at M G-D lab is currently supported by Grants PGC2018-094232-B-I00 funded by MICIN/AEI/10.13039/501100011033, Spain, and CV20-93141 from regional government from Andalusia (both co-financed by the European Regional Development Fund, European Union)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SENP7 overexpression protects cancer cells from oxygen and glucose deprivation and associates with poor prognosis in colon cancer

  • Gallardo-Chamizo, Francisco
  • Lara-Ureña, Nieves
  • Correa-Vázquez, Juan F.
  • Reyes, José C.
  • Gauthier, Benoit R.
  • García-Domínguez, Mario
To the Editor, Constricted oxygen and glucose supplies are common conditions that healthy cells following a stress such an ischemic insult as well as cancer cells within a solid tumor need to overcome in order to survive. These conditions are a serious challenge for cells, which accurately measure the impact to make a life or death decision. In cancer cells, aberrant gene expression and/or protein regulation, frequently linked to appearing mutations, may confer selective advantages to survive under these adverse conditions. In the past years, cumulative evidence indicates that protein modification by covalent attachment of the Small Ubiquitin-like MOdifier (SUMO) plays a role in cell survival after oxygen and glucose deprivation (OGD).1 Sumoylation involves maturation of SUMO, E1 (SAE1/UBA2)-mediated activation and transfer to the E2 conjugating enzyme (UBC9), to be attached to target proteins, which is frequently facilitated by a E3 ligase, with PIAS as the most investigated proteins.2 Specific SUMO proteases such as the SENP family members are involved in maturation and recycling SUMO from targets.2 SUMO is essential in vertebrates, participates in most physiological processes and is associated with cancer.2 Three functional SUMO molecules have been identified in humans: SUMO1, 2 and 3. SUMO2 and 3, usually referred to as SUMO2/3, are highly homologous and undistinguishable, and are abundant in the cell as unconjugated to rapidly modify proteins in response to OGD.1 From the initial observation of increased SUMO2/3 conjugation in squirrel brain during hibernation torpor a number of reports have described protection effects of sumoylation in ischemic/reperfusion models, and established better outcomes in cell viability associated with SUMO or UBC9 overexpression and worse outcomes associated with SUMO silencing or SENP1 overexpression.1 However, sumoylation of heterochromatin protein 1 α (HP1α) has been linked to senescence in cancer cells.3 To define molecular relevant aspects of SUMO-mediated response to OGD, we have investigated gene expression regulation of the sumoylation pathway components. Notably we found that Senp7 gene and protein are downregulated in OGD-treated cancer cells. Interestingly, SENP7 overexpression under these conditions increased cell survival, while downregulation potentiated OGD-triggered apoptosis. In contrast, SENP3 promoted cell death. These observations are in agreement with prevalent amplification of SENP7 and deletion of SENP3 genomic regions in many cancer types. More importantly, in colon cancer, high expression of SENP7 correlated with both, poor prognosis and higher transformation degree., This work was supported by MICIN/AEI/10.13039/501100011033, Spain/ERDF “A way to make Europe”, European Union (No. PGC2018-094232-B-I00); CEICE, Junta de Andalucía, Spain (No. CTS 2064). JF C–V was supported by MICIN/AEI/10.13039/501100011033, Spain/ESF “Investing in your future”, European Union (contract No. BES-2016-076500).